|
1) Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des. 2004; 10: 1469-92
|
|
|
|
2) Lockhart A. Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today. 2006; 11: 1093-9
|
|
|
|
|
|
3) Okamura N, Suemoto T, Shimadzu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004; 24: 2535-41
|
|
|
|
|
|
4) Ye L, Morgenstern JL, Gee AD, et al. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem. 2005; 280: 23599-604
|
|
|
|
|
|
5) Lockhart A, Ye L, Judd DB, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem. 2005; 280: 7677-84
|
|
|
|
|
|
6) Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkyl-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J Neurosci. 2001; 21: RC189
|
|
|
|
|
|
7) Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2002; 10: 24-35
|
|
|
|
|
|
8) Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006; 355: 2652-63
|
|
|
|
|
|
9) Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003; 46: 2740-54
|
|
|
|
|
|
10) Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheier's disease with Pittsburgh compound-B. Ann Neurol. 2004; 55: 306- 19
|
|
|
|
|
|
11) Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-βin Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005; 25: 10598-606
|
|
|
|
|
|
12) Klunk WE, Wang Y, Huang G, et al. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003; 23: 2086-92
|
|
|
|
|
|
13) Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab. 2005; 25: 1528-47
|
|
|
|
|
|
14) Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005; 46: 1959-72
|
|
|
|
|
|
15) Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006; 67: 1575-80
|
|
|
|
|
|
16) Ziolko SK, Weissfeld LA, Klunk WE, et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006; 33: 94-102
|
|
|
|
|
|
17) Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007; 68: 1603-6
|
|
|
|
|
|
18) Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2007; [Epub ahead of print]
|
|
|
|
|
|
19) Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease. Neurology. 2007; 68: 501-8
|
|
|
|
|
|
20) Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006; 59: 512-9
|
|
|
|
|
|
21) Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006; 60: 145-7
|
|
|
|
|
|
22) Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006; 129: 2856-66
|
|
|
|
|
|
23) Mintun MA, LaRossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006; 67: 446-52
|
|
|
|
|
|
24) Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27: 6174-84
|
|
|
|
|
|
25) Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007; 68: 1205-12
|
|
|
|
|
|
26) Rowe CC, Ackermann U, Gong SJ, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68: 1718-25
|
|
|
|
|
|
27) Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007; 64: 431-4
|
|
|
|
|
|
28) Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology. 2007; 69: 283-90
|
|
|
|
|
|
29) Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004; 12: 584-95
|
|
|
|
|
|
30) Kudo Y, Okamura N, Furumoto S, et al. 2-(2- [2-dimethylaminothiazol-5-yl]-6-(2-[fluoro] ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007; 48: 553-61
|
|
|
|
|
|
31) Rowe CC, Ng S, Mulligan RS, et al. Initial results from human studies of a novel F-18 PET ligand for brain beta-amyloid imaging. Alz Dement. 2007; 3 (suppl 2): S173
|
|
|
|
|
|
32) Marek K, Jennings D, Tamagnan G, et al. [123I]IMPY imaging in Alzheimer's disease and healthy controls. Alz Dement. 2007; 3 (suppl 2): S112
|
|
|
|
|
|
33) Higuchi M, Iwata N, Matsuba Y, et al. 19F and 1H MRI detection of amyloid β plaques in vivo. Nature Neurosci. 2005; 8: 527-33
|
|
|
|
|
|
34) Nakada T, Matsuzawa H, Igarashi H, et al. Direct visualization of senile plaques of patients in vivo by magnetic resonance microscory on a 7T clinical system. Neurology. 2007; 68 (Suppl 1): A98
|
|
|
|
|
|
35) O'Brien JT, Colloby SJ, Pakrasi S, et al. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry. 2007; 78: 356-62
|
|
|
|
|
|
36) Kepe V, Barrio JR, Huang SC, et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2006; 103: 702-7
|
|
|
|
|
|
37) Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001; 358: 461-7
|
|
|
|
|
|
38) Ikoma Y, Yasuno F, Ito H, et al. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [11C]DAA1106. J Cereb Blood Flow Metab. 2007; 27: 173-84
|
|
|
|
|